Steve CohenSell
Emergent BioSolutions Inc. Common Stock · Transaction Dec 11, 2024 · Filed Jan 10, 2025 · $1,001 to $15,000
NEW YORK STOCK EXCHANGE, INC. · EBS
+0.37% · +$0.0300 · Vol 47.1K
Live · updated 10:15:17 ET
Emergent BioSolutions Inc
Biotechnology
$6.70
Follow $EBS
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $EBS by emailVeridion Score
BETALOW CONF · 6 of 6 factors measuredWed Sep 23 · last completed session · daily score · 14h old · EBS
MethodologyEBS
Emergent BioSolutions Inc
Wed Sep 23 · last completed session · daily score · 14h old
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
59/ 100
Veridion Score
Middle range · LOW confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6 of 6 factors measured · Wed Sep 23 · last completed session · daily score · 14h old
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is EBS moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Emergent BioSolutions Inc
PHARMACEUTICAL PREPARATIONSListed since
2006
Employees
900
Country
US
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$6.60
Day high
$6.70
Day low
$6.56
Previous close
$6.67
52W high
$13.90
-51.83% from high
52W low
$4.45
24% of range
Market cap
$342M
P/E
6.68×
EPS
$-2.7300
Beta
0.28
Shares out
51.3M
Volume
47.1K
0.04× rel vol
Avg volume
1.2M
VWAP
$6.63
Price history computed in-house
1W
-4.63%
1M
+18.71%
3M
-21.51%
1Y
-19.24%
YTD
-45.83%
SMA 50 $6.27 · above
SMA 200 $8.78 · below
52W position 24%
EBS overview
Related filings and maps
Public disclosures
Congress activity in EBS
Official filing ↗
Steve CohenSell
EBS · Transaction Dec 11, 2024 · Filed Jan 10, 2025 · $1,001 to $15,000
Federal contracts
EBS contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for EBS in this window.
Lobbying spend
EBS lobbying filings, year to date.
Registered lobbying filings matched to Emergent BioSolutions Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for EBS in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for EBS.
Options
Sovereign unlock shows live options positioning for EBS.